DC-CIK与结直肠癌患者预后的关系和影响因素

操跃; 杨喜晶; 周福平; 张迁; 钱其军

doi:10.3969/j.issn.1006-0111.2016.04.022

DC-CIK与结直肠癌患者预后的关系和影响因素

doi: 10.3969/j.issn.1006-0111.2016.04.022

1.
福建医科大学第一临床医学院, 福建福州 350108
2.
第二军医大学附属东方肝胆外科医院生物治疗科, 上海 200438

基金项目: 上海市卫生局重点项目（20134018）

The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors

1.
First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China
2.
Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

摘要: 目的探讨树突状细胞-细胞因子诱导的杀伤细胞（dendritic cell-cytokine-induced killers，DC-CIK）治疗与结直肠癌患者预后的关系，以便更好地为临床治疗提供参考。方法回顾性分析东方肝胆外科医院生物治疗科2012年1月至2014年1月收治的66例结直肠癌患者信息，随访。在以性别、年龄、病理分化程度、TNM分期、接受手术的方式及是否接受靶向治疗为研究基础上，通过Kaplan-Meier单因素和Cox多因素分析，重点探讨DC-CIK治疗对患者预后的影响。结果 Kaplan-Meier单因素分析结果提示：接受DC-CIK治疗在一定程度上能改善患者的预后；Cox多因素分析结果提示：是否接受DC-CIK治疗是影响患者预后的独立因素。结论接受DC-CIK治疗可改善结直肠癌患者的预后。
- 结直肠癌 /
- 预后 /
- 树突状细胞-细胞因子诱导的杀伤细胞 /
- 药物靶向治疗
Abstract: Objective To discuss dendritic cell-cytokine-induced killer (DC-CIK) cell therapy effects and clinical outcomes in patients with colorectal cancer in order to have better clinical treatment. Methods A retrospective analysis of the data of 66 patients with colorectal cancer from the Biological Therapy Department of the Eastern Hepatobiliary Surgery Hospital was performed from January 2012 to January 2014, and then was followed up. Taking gender, age, degree of pathological differentiation, TNM staging, surgical methods, and targeted therapy as the research basis, by the Kaplan-Meier single factor and Cox multiple factors analysis we mainly discuss the DC-CIK cell treatment's effect on the prognoses of patients. Results Kaplan-Meier single factor analysis results indicate:to a certain extent, DC-CIK cell therapy can improve the prognoses of patients; Cox multi-factor analysis results indicate whether accepting DC-CIK cell therapy is an independent factor influencing the prognoses of patients. Conclusion DC-CIK cells therapy can improve the prognoses of patients with colorectal cancer.
- colorectal cancer /
- prognosis /
- dendritic cell-cytokine-induced killers (DC-CIK) /
- drug targeting therapy

[1]	陈勇. 口服单药希罗达与FOLFOX方案治疗晚期结直肠癌的疗效比较[J]. 中国药业,2012,21(11):90-91.
[2]	Thara E, Dorff TB, Pinski JK, et al. Vaccine therapy with sipuleucel-T (provenge) for prostate cancer[J]. Maturitas,2011,69(4):296-303.
[3]	Fox BA, Schendel DJ, Butterfield LH, et al. Defining the critical hurdles in cancer immunotherapy[J]. J Transl Med,2011,9:214.
[4]	Bol KF, Tel J, de Vries IJM, et al. Naturally circulating dendritic cells to vaccinate cancer patients[J]. Oncoimmunology,2013,2(3):e23431.
[5]	Tel J, Smits EL, Anguille S, et al. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities[J]. Blood,2012,120(19):3936-3944.
[6]	Wang X, Yu W, Li H, et al. Can the dual-functional capability of CIK cells be used to improve antitumor effects?[J]. Cell Immunol,2014,287(1):18-22.
[7]	Frankenberger B, Schendel DJ. Third generation dendritic cell vaccines for tumor immunotherapy[J]. Eur J Cell Biol,2012,91(1):53-58.
[8]	Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opin Biol Ther,2012,12(6):673-684.
[9]	Jakel CE, Hauser S, Rogenhofer S, et al. Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma[J]. Clin Dev Immunol,2012,2012:473245.
[10]	Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opin Biol Ther,2012,12(6):673-684.
[11]	Shi S, Wang R, Chen Y, et al. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models[J]. PLoS One,2013,8(6):e65757.
[12]	Hasumi K, Aoki Y, Wantanabe R, et al. Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy[J]. Oncoimmunology,2013,2(10):e26381.
[13]	Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells:first report of the international registry on CIK cells (IRCC)[J]. J Cancer Res Clin Oncol,2011,137(2):305-310.
[14]	Thanendrarajan S, Nowak M, Abken H, et al. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy:more than one plus one?[J]. Leuk Res,2011,35(9):1136-1142.
[15]	Schlom J. Recent advances in therapeutic cancer vaccines[J]. Cancer Biother Radiopharm,2012,27(1):2-5.
[16]	Marten A, Renoth S, von Lilienfeld-Toal M, et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells[J]. Haematologica,2001,86(10):1029-1037.
[17]	Xiang B, Snook AE, Magee MS, et al. Colorectal cancer immunotherapy[J]. Discov Med,2013,15(84):301-308.
[18]	Toomey PG, Vohra NA, Ghansah T, et al. Immunotherapy for gastrointestinal malignancies[J]. Cancer Control,2013,20(1):32-42.
[19]	Cui Y, Yang X, Zhu W, et al. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients[J]. Oncol Lett,2013,6(2):537-541.
[20]	Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opin Biol Ther,2012,12(6):673-684.
[21]	Duru N, Fan M, Candas D, et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells[J]. Clin Cancer Res,2012,18(24):6634-6647.
[22]	Beutler N, Hauka S, Niepel A, et al. A natural tapasin isoform lacking exon 3 modifies peptide loading complex function[J]. Eur J Immunol,2013,43(6):1459-1469.

[1]	王鹏, 吴宗贵, 张争艳. 活心丸（浓缩丸）联合八段锦对急性心肌梗死合并心衰介入术后预后的影响 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202308034
[2]	方宇昕, 李育, 刘宝姝, 董国强. 磷脂酰肌醇蛋白聚糖-3靶向治疗肝细胞癌的研究进展 . 药学实践与服务, 2023, 41(10): 586-593. doi: 10.12206/j.issn.2097-2024.202307047
[3]	黄文辉, 许燕玉, 郝晓伟, 林冠, 欧阳山丹, 王佳坤, 陈锦珊. 奈玛特韦片/利托那韦片治疗COVID-19早期预后不良的危险因素及预测模型构建 . 药学实践与服务, 2023, 41(11): 700-704. doi: 10.12206/j.issn.2097-2024.202303038
[4]	刘艳平, 王志鹏, 崔莉莉, 许封菁, 张蒙伟, 高守红. 卡培他滨致手足综合征严重程度与血浆中炎症因子含量的分析 . 药学实践与服务, 2023, 41(10): 634-637. doi: 10.12206/j.issn.2097-2024.202108129
[5]	田硕, 厉建中. ZNF24基因过表达慢病毒载体的构建及其在人结直肠癌HCT116细胞中的表达 . 药学实践与服务, 2023, 41(4): 222-226. doi: 10.12206/j.issn.2097-2024.202204040
[6]	王晓丹, 马骁龙, 董文星. 乌司他丁对感染性休克患者炎症反应、血流动力学、PaO₂/FiO₂及预后的影响 . 药学实践与服务, 2022, 40(6): 576-579. doi: 10.12206/j.issn.2097-2024.202206091
[7]	黄静静, 陈浩, 李霖睿, 罗助荣, 林衔亮. 麝香保心丸联合冠脉内注射尼可地尔对STEMI患者PPCI术后心肌血流灌注及近期预后的影响 . 药学实践与服务, 2022, 40(1): 79-83. doi: 10.12206/j.issn.1006-0111.202008009
[8]	赵景昕, 缪朝玉, 徐添颖. 脓毒症生物标志物的最新进展 . 药学实践与服务, 2021, 39(6): 491-498. doi: 10.12206/j.issn.1006-0111.202105040
[9]	陈炳辰, 于恩达. 增强紫杉醇对结直肠癌化疗疗效的研究进展 . 药学实践与服务, 2020, 38(6): 501-505. doi: 10.12206/j.issn.1006-0111.202007031
[10]	袁颖超, 廖秋菊. 炎性细胞因子与膝骨关节炎诊断及治疗的最新研究进展 . 药学实践与服务, 2018, 36(1): 9-12. doi: 10.3969/j.issn.1006-0111.2018.01.002
[11]	刘曼, 刘丽云, 孙凡, 林厚文. 靶向肺癌干细胞的海绵抗肿瘤活性化合物的发现 . 药学实践与服务, 2017, 35(4): 304-307. doi: 10.3969/j.issn.1006-0111.2017.04.005
[12]	王婧, 方宏亮, 黄金路, 郭澄. 缺失错配修复基因MLH1的结直肠癌HCT唱116细胞对氟尿嘧啶耐药机制的研究 . 药学实践与服务, 2017, 35(2): 121-125. doi: 10.3969/j.issn.1006-0111.2017.02.006
[13]	王洁, 黄岩, 张川, 马兴元, 常文军, 陆一鸣. 氟尿嘧啶对结直肠癌RKO细胞SHP2基因表达的影响 . 药学实践与服务, 2017, 35(6): 512-515. doi: 10.3969/j.issn.1006-0111.2017.06.008
[14]	姜文丽, 黄才国. 晚期非小细胞肺癌靶向治疗的研究进展 . 药学实践与服务, 2016, 34(4): 301-304,333. doi: 10.3969/j.issn.1006-0111.2016.04.004
[15]	蒋琦, 钱其军. 化疗药物靶向肿瘤相关免疫抑制性细胞的研究进展 . 药学实践与服务, 2015, 33(2): 163-166,182. doi: 10.3969/j.issn.1006-0111.2015.02.019
[16]	王真, 徐增辉, 郑罗凝, 王颖, 孙保木, 金华君, 钱其军. 肝细胞癌循环肿瘤细胞与肿瘤转移和预后关系的研究 . 药学实践与服务, 2015, 33(2): 159-162,192. doi: 10.3969/j.issn.1006-0111.2015.02.018
[17]	黄景彬, 钟延强. 乳腺癌靶向治疗的新策略 . 药学实践与服务, 2011, 29(5): 324-327.
[18]	薛龙, 孙爱军. 恶性肿瘤靶向治疗方法的进展及应用 . 药学实践与服务, 2008, (2): 81-83.
[19]	成冰燕, 王占元. 细胞因子与类风湿性关节炎治疗的研究进展 . 药学实践与服务, 2000, (3): 143-144.
[20]	李以欣. 细胞增殖分化因子及其作为药物的应用 . 药学实践与服务, 1991, (3): 21-24.

点击查看大图

计量

文章访问数: 3236
HTML全文浏览量: 280
PDF下载量: 955
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

DC-CIK与结直肠癌患者预后的关系和影响因素

doi: 10.3969/j.issn.1006-0111.2016.04.022

The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors

计量

DC-CIK与结直肠癌患者预后的关系和影响因素

doi: 10.3969/j.issn.1006-0111.2016.04.022

1. 福建医科大学第一临床医学院, 福建福州 350108

2. 第二军医大学附属东方肝胆外科医院生物治疗科, 上海 200438

English Abstract

The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors

1. First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China

2. Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

全文HTML

目录

留言板

DC-CIK与结直肠癌患者预后的关系和影响因素

doi: 10.3969/j.issn.1006-0111.2016.04.022

The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors

计量

出版历程

DC-CIK与结直肠癌患者预后的关系和影响因素

doi: 10.3969/j.issn.1006-0111.2016.04.022

1. 福建医科大学第一临床医学院, 福建 福州 350108 2. 第二军医大学附属东方肝胆外科医院生物治疗科, 上海 200438

English Abstract

The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors

1. First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China 2. Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

全文HTML

目录

1. 福建医科大学第一临床医学院, 福建福州 350108

2. 第二军医大学附属东方肝胆外科医院生物治疗科, 上海 200438

1. First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China

2. Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China